Combating Multidrug-Resistant Gram-Negative Bacteria Using Biofilm Protein Pase 1 as Novel Dispersal Agent for Co-Treatment Therapy

The emergence of antimicrobial resistance genes in multidrug-resistant gram-negative (MDRGN) bacteria leads to an immense increase in mortality rates and poses a major threat to global health. Current treatment methods and even drugs of last resort (DoLRs) have failed to successfully treat these infections, warranting the need for a new and immediate solution. This study focuses on the synthesis and investigation of an optimal dispersal agent for co-treatment. Previous screening of the genome of Acinetobacter baumannii, a highly virulent nosocomial gram-negative pathogen of ESKAPE, identified the hypothetical gene segment Pase 1 with potential characteristics of bacterial dispersion. Through treatment of various multidrug-resistant gram-negative bacterial biofilms and ESKAPE pathogens, the results indicated that AB-Pase 1 exhibited optimal characteristics as a co-treatment dispersal agent, with higher dispersion percentages and controlled dispersal rates in comparison to E. coli-Pase 1. Therefore, with the expansion of AB-Pase 1 in co-treatment therapy, there is an immense potential for successfully combating multi-resistant bacteria, a crucial breakthrough in the medical field.